Global Intramuscular Vaccine Adjuvants 麻豆原创 Growth 2025-2031

Publication ID:

LPI02253787

Publication Date:

February 27, 2025

Pages:

118

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Intramuscular Vaccine Adjuvants market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Intramuscular Vaccine Adjuvants is used for Intramuscular injection of Vaccine Adjuvants. A vaccine adjuvant is any material which is incorporated with a vaccine for the purpose of enhancing the immune response of the vaccine. An adjuvanted vaccine will tend to have a higher, earlier, and longer-lasting immune response than a non-adjuvanted vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淚ntramuscular Vaccine Adjuvants Industry Forecast鈥� looks at past sales and reviews total world Intramuscular Vaccine Adjuvants sales in 2024, providing a comprehensive analysis by region and market sector of projected Intramuscular Vaccine Adjuvants sales for 2025 through 2031. With Intramuscular Vaccine Adjuvants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intramuscular Vaccine Adjuvants industry.
This Insight Report provides a comprehensive analysis of the global Intramuscular Vaccine Adjuvants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Intramuscular Vaccine Adjuvants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Intramuscular Vaccine Adjuvants market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intramuscular Vaccine Adjuvants and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intramuscular Vaccine Adjuvants.
This report presents a comprehensive overview, market shares, and growth opportunities of Intramuscular Vaccine Adjuvants market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Infectious Diseases
Cancer
Others
Segmentation by Application:
Research Applications
Commercial Applications
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
Dynavax Technologies
Novavax
Agenus
Croda International
Seppic
OZ Biosciences
Phibro Animal Health
Associated British Foods
InvivoGen
Merck KGaA
CSL Limited
Key Questions Addressed in this Report
What is the 10-year outlook for the global Intramuscular Vaccine Adjuvants market?
What factors are driving Intramuscular Vaccine Adjuvants market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Intramuscular Vaccine Adjuvants market opportunities vary by end market size?
How does Intramuscular Vaccine Adjuvants break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Intramuscular Vaccine Adjuvants Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Intramuscular Vaccine Adjuvants by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Intramuscular Vaccine Adjuvants by Country/Region, 2020, 2024 & 2031
2.2 Intramuscular Vaccine Adjuvants Segment by Type
2.2.1 Infectious Diseases
2.2.2 Cancer
2.2.3 Others
2.3 Intramuscular Vaccine Adjuvants Sales by Type
2.3.1 Global Intramuscular Vaccine Adjuvants Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Intramuscular Vaccine Adjuvants Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Intramuscular Vaccine Adjuvants Sale Price by Type (2020-2025)
2.4 Intramuscular Vaccine Adjuvants Segment by Application
2.4.1 Research Applications
2.4.2 Commercial Applications
2.5 Intramuscular Vaccine Adjuvants Sales by Application
2.5.1 Global Intramuscular Vaccine Adjuvants Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Intramuscular Vaccine Adjuvants Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Intramuscular Vaccine Adjuvants Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Intramuscular Vaccine Adjuvants Breakdown Data by Company
3.1.1 Global Intramuscular Vaccine Adjuvants Annual Sales by Company (2020-2025)
3.1.2 Global Intramuscular Vaccine Adjuvants Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Intramuscular Vaccine Adjuvants Annual Revenue by Company (2020-2025)
3.2.1 Global Intramuscular Vaccine Adjuvants Revenue by Company (2020-2025)
3.2.2 Global Intramuscular Vaccine Adjuvants Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Intramuscular Vaccine Adjuvants Sale Price by Company
3.4 Key Manufacturers Intramuscular Vaccine Adjuvants Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Intramuscular Vaccine Adjuvants Product Location Distribution
3.4.2 Players Intramuscular Vaccine Adjuvants Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Intramuscular Vaccine Adjuvants by Geographic Region
4.1 World Historic Intramuscular Vaccine Adjuvants 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Intramuscular Vaccine Adjuvants Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Intramuscular Vaccine Adjuvants Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Intramuscular Vaccine Adjuvants 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Intramuscular Vaccine Adjuvants Annual Sales by Country/Region (2020-2025)
4.2.2 Global Intramuscular Vaccine Adjuvants Annual Revenue by Country/Region (2020-2025)
4.3 Americas Intramuscular Vaccine Adjuvants Sales Growth
4.4 APAC Intramuscular Vaccine Adjuvants Sales Growth
4.5 Europe Intramuscular Vaccine Adjuvants Sales Growth
4.6 Middle East & Africa Intramuscular Vaccine Adjuvants Sales Growth
5 Americas
5.1 Americas Intramuscular Vaccine Adjuvants Sales by Country
5.1.1 Americas Intramuscular Vaccine Adjuvants Sales by Country (2020-2025)
5.1.2 Americas Intramuscular Vaccine Adjuvants Revenue by Country (2020-2025)
5.2 Americas Intramuscular Vaccine Adjuvants Sales by Type (2020-2025)
5.3 Americas Intramuscular Vaccine Adjuvants Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Intramuscular Vaccine Adjuvants Sales by Region
6.1.1 APAC Intramuscular Vaccine Adjuvants Sales by Region (2020-2025)
6.1.2 APAC Intramuscular Vaccine Adjuvants Revenue by Region (2020-2025)
6.2 APAC Intramuscular Vaccine Adjuvants Sales by Type (2020-2025)
6.3 APAC Intramuscular Vaccine Adjuvants Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Intramuscular Vaccine Adjuvants by Country
7.1.1 Europe Intramuscular Vaccine Adjuvants Sales by Country (2020-2025)
7.1.2 Europe Intramuscular Vaccine Adjuvants Revenue by Country (2020-2025)
7.2 Europe Intramuscular Vaccine Adjuvants Sales by Type (2020-2025)
7.3 Europe Intramuscular Vaccine Adjuvants Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Intramuscular Vaccine Adjuvants by Country
8.1.1 Middle East & Africa Intramuscular Vaccine Adjuvants Sales by Country (2020-2025)
8.1.2 Middle East & Africa Intramuscular Vaccine Adjuvants Revenue by Country (2020-2025)
8.2 Middle East & Africa Intramuscular Vaccine Adjuvants Sales by Type (2020-2025)
8.3 Middle East & Africa Intramuscular Vaccine Adjuvants Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Intramuscular Vaccine Adjuvants
10.3 Manufacturing Process Analysis of Intramuscular Vaccine Adjuvants
10.4 Industry Chain Structure of Intramuscular Vaccine Adjuvants
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Intramuscular Vaccine Adjuvants Distributors
11.3 Intramuscular Vaccine Adjuvants Customer
12 World Forecast Review for Intramuscular Vaccine Adjuvants by Geographic Region
12.1 Global Intramuscular Vaccine Adjuvants 麻豆原创 Size Forecast by Region
12.1.1 Global Intramuscular Vaccine Adjuvants Forecast by Region (2026-2031)
12.1.2 Global Intramuscular Vaccine Adjuvants Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Intramuscular Vaccine Adjuvants Forecast by Type (2026-2031)
12.7 Global Intramuscular Vaccine Adjuvants Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.1.3 GSK Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Dynavax Technologies
13.2.1 Dynavax Technologies Company Information
13.2.2 Dynavax Technologies Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.2.3 Dynavax Technologies Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Dynavax Technologies Main Business Overview
13.2.5 Dynavax Technologies Latest Developments
13.3 Novavax
13.3.1 Novavax Company Information
13.3.2 Novavax Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.3.3 Novavax Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novavax Main Business Overview
13.3.5 Novavax Latest Developments
13.4 Agenus
13.4.1 Agenus Company Information
13.4.2 Agenus Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.4.3 Agenus Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Agenus Main Business Overview
13.4.5 Agenus Latest Developments
13.5 Croda International
13.5.1 Croda International Company Information
13.5.2 Croda International Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.5.3 Croda International Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Croda International Main Business Overview
13.5.5 Croda International Latest Developments
13.6 Seppic
13.6.1 Seppic Company Information
13.6.2 Seppic Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.6.3 Seppic Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Seppic Main Business Overview
13.6.5 Seppic Latest Developments
13.7 OZ Biosciences
13.7.1 OZ Biosciences Company Information
13.7.2 OZ Biosciences Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.7.3 OZ Biosciences Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 OZ Biosciences Main Business Overview
13.7.5 OZ Biosciences Latest Developments
13.8 Phibro Animal Health
13.8.1 Phibro Animal Health Company Information
13.8.2 Phibro Animal Health Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.8.3 Phibro Animal Health Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Phibro Animal Health Main Business Overview
13.8.5 Phibro Animal Health Latest Developments
13.9 Associated British Foods
13.9.1 Associated British Foods Company Information
13.9.2 Associated British Foods Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.9.3 Associated British Foods Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Associated British Foods Main Business Overview
13.9.5 Associated British Foods Latest Developments
13.10 InvivoGen
13.10.1 InvivoGen Company Information
13.10.2 InvivoGen Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.10.3 InvivoGen Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 InvivoGen Main Business Overview
13.10.5 InvivoGen Latest Developments
13.11 Merck KGaA
13.11.1 Merck KGaA Company Information
13.11.2 Merck KGaA Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.11.3 Merck KGaA Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Merck KGaA Main Business Overview
13.11.5 Merck KGaA Latest Developments
13.12 CSL Limited
13.12.1 CSL Limited Company Information
13.12.2 CSL Limited Intramuscular Vaccine Adjuvants Product Portfolios and Specifications
13.12.3 CSL Limited Intramuscular Vaccine Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 CSL Limited Main Business Overview
13.12.5 CSL Limited Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.